A study published in 2023 indicated that GW9662, a PPARγ antagonist, alleviated hepatic steatosis by suppressing the PPARγ2–CD36 pathway, consequently slowing the progression of MASLD [60]. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.